Fast Titration Of Quetiapine Versus Currently Approved Titration

AstraZeneca150 enrolled

Overview

The purpose of this study is to evaluate the safety and tolerability of a more rapid dose titration in acute schizophrenic patients compared to the conventional titration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

150

Conditions

Psychotic Disorders

Interventions

QuetiapineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Signed informed consent, male or female between 18 and 60 years old, having acute exacerbation of their schizophrenia or schizoaffective disorder requiring admission to hospital. Should stay in hospital for at least 7 days. Exclusion Criteria: * Patients treated with Risperdal consta or Clozapine last 28 days, pregnancy or breast-feeding, patients known to be intolerant or unresponsive to quetiapine, known arrhythmia, other serious medical conditions.

Locations (7)

Research Site

Arendal, Norway

Research Site

Ålesund, Norway

Research Site

Klepp stasjon, Norway

Research Site

Kristiansand, Norway

Research Site

Outcomes

Primary Outcomes

Proportion of patients with moderate and severe adverse events

Secondary Outcomes

Mean daily level of somnolence and orthostatic dizziness as rated on AE intensity scale

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.